Eculizumab biosimilar - Amgen
Alternative Names: ABP 959; BEKEMV; BkemvLatest Information Update: 05 Jun 2024
At a glance
- Originator Amgen
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 28 May 2024 Registered for Haemolytic uraemic syndrome in USA (IV)
- 28 May 2024 Registered for Paroxysmal nocturnal haemoglobinuria in USA (IV)
- 09 Dec 2023 Pharmacokinetics data from a phase III DAHLIA trial in Paroxysmal nocturnal haemoglobinuria presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)